|
Revealing the significance of NLRP3/Colchicine/Canakinumab to transform atherosclerotic plaques by suppressing inflammation.
Dr Ben Chen
Dr. Chen is a qualified veterinary surgeon, mid-career researcher, and a group leader in the preclinical drug testing team at the Victoria Heart Institute. He led a discovery team consisting of two PhDs, one Honours student, and one RA for testing several lines of new therapeutics and gut microbiome intervention. He designed, developed, and validated the first TS mouse model and is the leading expert in its use. The model was ranked in the top 10 most-read articles published in Circulation Research in 2013. He has made groundbreaking discoveries about modulating shear stress for the development of vulnerable plaques. His second animal model of diabetes TS (published in JAHA in 2022) received over 3,500 downloads and was cited 13 times within 1.5 year. He was the receipient of numerous Fellowships including the Heart Foundation Postdoctoral Fellowship, the prestigious Paul Korner Innovation Award, Heart foundation Future Leader Fellowship, and the prestigious Baker 5-year fellowship. Leading multiple funded projects He has authored 33 papers (First in EHJ, Circ Res, Nature Comm, ATVB, CVR, THx2, JAHA, FASEB J, Commun Biol, Senior in Mol Cell Proteomics), 6 reviews, 1 book chapter, and holds 8 patents with over 3,400 citations (H-index 30, Scopus).
|
